Responsiveness to change and interpretability of the simplified psoriasis index

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 351-358

  Chularojanamontri, Leena ^a,b   Griffiths, Christopher E M ^a   Chalmers, Robert J G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETRETIN; METHOTREXATE;

ADULT; ARTICLE; CLINICAL DECISION MAKING; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SIMPLIFIED PSORIASIS INDEX;

ADULT; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84892809714     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.318     Document Type: Article

References (18)

1. Beaton DE, Eerd DV, Smith P et al. (2010) Minimal change is sensitive, less specific to recovery: A diagnostic testing approach to interpretability. J Clin Epidemiol 64:487-96
2. Carlin CS, Feldman SR, Krueger JG et al. (2004) A 50% reduction in Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50:859-66
3. Chularojanamontri L, Griffiths CEM, Chalmers RJG (2013) The Simplified Psoriasis Index: A practical tool for assessing psoriasis. J Invest Dermatol 133:1956-62
4. Hanley JA (1988) The robustness of the ''binormal'' assumptions used in fitting ROC curves. Med Decis Making 8:197-203
5. Jensen JD, Fujita M, Dellavalle RP (2011) Validation of psoriasis clinical severity and outcome measures: Searching for a gold standard. Arch Dermatol 147:95-8
6. Katz KA (2005) Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: An unconvincing proposal. J Am Acad Dermatol 53:547-51
7. Kirby B, Fortune DG, Bhushan M et al. (2000) The Salford Psoriasis Index: An holistic measure of psoriasis severity. Br J Dermatol 142:728-32
8. Loveman E, Turner D, Hartwell D et al. (2009) Infliximab for the treatment of adults with psoriasis. Health Technol Assess 13(Suppl 1):55-60
9. Mokkink LB, Terwee CB, Knol DL et al. (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content. BMC Med Res Methodol 10:22
10. Naldi L (2010) Scorin thg and monitoring the severity of psoriasis. What is preferred method? What is the ideal method? Is PASI passe? facts and controversies. Clin Dermatol 28:67-72
11. Prinsen CA, Lindeboom R, Sprangers MAG et al. (2010) Health-related quality of life assessment in dermatology: Interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol 130:1318-22
12. Reich K, Nestle FO, Papp K et al. (2005) Infliximab induction and maintenance therapy for moderate-To-severe plaque-Type psoriasis: A phase III, multicentre, double-blind trial. Lancet 366:1367-74
13. Revicki D, Hays RD, Cella D et al. (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61:102-9
14. Spuls PI, Lectuse LL, Poulsen ML et al. (2010) How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systemic review. J Invest Dermatol 130:933-43
15. Turner D, Schunemann HJ, Griffith LE et al. (2009) Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference. J Clin Epidemiol 62:374-9
16. Turner D, Schunemann HJ, Griffith LE et al. (2010) The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 63:28-36
17. van de Kerkhof PC, Kragballe K, Austad J et al. (2006) Psoriasis: Severity assessment in clinical practice. Conclusion from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 16:167-71
18. Wyrwich KW, Wolinsky FD (2000) Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract 53:279-84